Posted: October 25, 2019
Frederick West, Ph.D. in the Department of Chemistry and David Marchant, Ph.D. in the Department of Medical Microbiology and Immunology discovered a new class of small molecule inhibitors against Zika and respiratory syncytial virus (RSV). Currently there are no approved drugs or vaccines available for the treatment or prevention of infection by Zika and RSV. The newly discovered inhibitors have a broad antiviral effect and could be a potential treatment of other viruses. The researchers are working towards further refining the compounds for drug development. Marchant and his research team also invented a research tool for expressing a desired gene in a host cell.
TEC Edmonton worked with the researchers to license the technologies to Marchant’s University of Alberta spin-off company, Antibiddies Technologies Inc. Further development of the inventions is supported by funding from the Canadian Institutes of Health Research, The Li Ka Shing Institute of Virology and the Women and Children’s Health Research Institute.
• David Marchant, Ph.D., associate professor, Faculty of Medicine & Dentistry, University of Alberta, chief scientific officer, Antibiddies Technologies Inc.
• Leanne Bilawchuk, chief executive officer, Antibiddies Technologies Inc.
The TEC Edmonton Innovation Awards celebrate the success of University of Alberta researchers. In 2019, awards were presented to ten University of Alberta spin-off companies and nine research teams that received a US patent and have an industry partner.